An AI-Designed BCMA/FcRL5 Targeting TriTE Overcomes Antigen Escape and Outperforms BCMA-Directed Therapy in Multiple Myeloma (IMS 2026) - Aug 23, 2026 - Abstract #OA-05; Pres time: Sep 24, 2026; 11:24 AM - 11:36 AM; Location: Lomond Auditorium; Virtual (Live streamed); In Person; "Cytotoxicity was further enhanced in BCMA-knockout cells engineered to overexpress FcRL5; in this setting, CB-101 outperformed both Teclistamab and Cevostamab. CB-101, a BCMA/FcRL5 TriTE, demonstrated enhanced antitumor activity in vitro and in vivo, outperforming BCMA-directed therapy even at substantially lower doses and retaining efficacy in settings associated with antigen escape and drug resistance. Enabled by an AI-driven high-throughput discovery platform, this next-generation BCMA/FcRL5 TriTE with provocative preclinical data is now poised for clinical evaluation in MM and WM to improve outcomes."
IO biomarker • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Multiple Myeloma • Waldenstrom Macroglobulinemia
|
|
Jessica Encinas Mayoral1; Jian Cui2; Elena MarotoMartin3; Alice Mattinson4; Edward King4; Marina He1; Amanda Kofides1; Steven P. Treon1; Zachary Hunter5; Yulia Lampi4; Simon Bornschein4; Mehmet K. Samur6; Mariateresa Fulciniti6; Nikhil C. Munshi6
|